|
Re: Breakthrough Therapy Designation Application
|
|
Resverlogix Corp.
|
Dec 06, 2019 02:35PM
|
|
Re: something. anything.
|
1
|
Zenith Epigenetics
|
Mar 04, 2020 07:47AM
|
|
Re: Hepalink
|
2
|
Resverlogix Corp.
|
Oct 15, 2021 08:45PM
|
|
Re: Ethics Approval?
|
3
|
Resverlogix Corp.
|
Oct 12, 2021 06:29PM
|
|
Re: Full presentation:
|
3
|
Resverlogix Corp.
|
Nov 16, 2019 12:46PM
|
|
Re: something. anything.
|
4
|
Zenith Epigenetics
|
Mar 03, 2020 10:46AM
|
|
Re: AGM 2018 - Masila Notes
|
4
|
Resverlogix Corp.
|
Sep 13, 2018 07:53AM
|
|
Re: Resverlogix Expands Phase 2b Clinical Trial for COVID-19
|
5
|
Resverlogix Corp.
|
Feb 17, 2022 07:47AM
|
|
Re: Partnerships, Re: Motley Fool - Resverlogix one of three biotechs than can "Electrify your TFSA"
|
5
|
Resverlogix Corp.
|
Jun 26, 2018 10:45AM
|
|
Re: CityNews cover
|
6
|
Resverlogix Corp.
|
Jan 31, 2022 05:00PM
|
|
Re: Todays presentation
|
6
|
Resverlogix Corp.
|
May 12, 2021 12:47PM
|
|
Re: Todays presentation - Archman and paladin
|
8
|
Resverlogix Corp.
|
May 12, 2021 03:16PM
|
|
Re: Summary of Proposed BETonMACE2 design and timelines
|
8
|
Resverlogix Corp.
|
Feb 05, 2021 09:43AM
|
|
Re: Resverlogix Expands Phase 2b Clinical Trial for COVID-19
|
9
|
Resverlogix Corp.
|
Feb 17, 2022 08:13AM
|
|
Re: Success or Failure?
|
10
|
Resverlogix Corp.
|
Oct 06, 2019 01:16PM
|
